New drug development is aimed at the four major US$100 billion fields, and over 100 oncology drugs will be approved for marketing by 2025

Cancer and autoimmune diseases will not disappear

A report recently released by the IQVIA Institute of Human Data Science shows that with the expansion of demand in these therapeutic areas, its leading position as the first two areas of the healthcare industry has become increasingly obvious.

Looking back at the top-selling drug rankings in 2020, we can clearly prove the dominance of these fields

Although expenditures in many other disease areas are expected to grow by 5% per year in the next few years, they will not reach the expected compound annual growth rate of 9% to 12% in oncology and immunology

In the next few years, market observers expect that both areas will continue to introduce new drugs, and more patients will start taking existing drugs

By 2025, IQVIA expects that its annual expenditure on oncology will reach US$273 billion, far more than any other field

The expenditure in the field of immunology is the second place, with US$175 billion

It is followed closely by anti-diabetic drugs with USD 148 billion and neurological therapy with USD 143 billion

IQVIA said that by 2025, expenditures in other individual treatment areas will not exceed $75 billion

Since 2013, the annual growth rate has been double-digit.

"The rapid growth in the past few years is due to the launch of PD-1 and PD-L1s and their use in more and more indications

At the same time, because the products produced by biomarker-driven therapies will not be transformed into a wider range of uses, many new oncology drugs will be "narrower and narrower" in practical applications

In the field of immunology, the acceptance of new drugs and patients will drive spending growth, but biosimilar drugs will provide counteracting power

Over the past five years, immunology expenditures have grown at a rate of 17% per year, thanks to new and highly effective treatments for diseases such as rheumatoid arthritis, ulcerative colitis, Crohn’s disease and psoriasis

But there is another area that may not be noticed or easily overlooked: neurology

At the same time, diabetes treatment seems to have reached the limit of growth